Results 81 to 90 of about 18,481 (166)

YK-4-279 Induces Osteosarcoma Cell Cycle Arrest, DNA Damage Response, and Apoptosis by Regulating the MAPK Cascade. [PDF]

Drug Des Devel Ther
Wang W, Zhang Y, Jia X, Han L, Xin M.
europepmc   +1 more source

BRD4 inhibition suppresses histone H4 UFMylation to increase ferroptosis sensitivity through TXNIP. [PDF]

Cell Death Dis
Yang Z, Wang B, Guo B, Sun S, Li Y, Lu J, Cao X, Wang H, Wang X, Guo Y, Wu T.   +10 more
europepmc   +1 more source

CENPs in hepatocellular carcinoma: a comprehensive review of expression patterns, clinical correlations, and functional mechanisms. [PDF]

Am J Cancer Res
Zhou J, Yang G, Wang Z, Lv Y, Du W, Wang J, Zhang L, Zhang K, Zhang W, Li X.   +9 more
europepmc   +1 more source

Selected Potential Biomarkers in Laryngeal Cell Carcinomas. [PDF]

Cancers (Basel)
Paduch R, Klatka M, Klatka J.
europepmc   +1 more source

Mathematical analysis of G1/S sub-networks in hematopoietic proliferation: Sequential and lineage-specific activation. [PDF]

iScience
Hanel A, Abdelsalam A, Tollis S.
europepmc   +1 more source

MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression. [PDF]

Cell Death Dis
Paudel R, Goller S, Deutzmann F, Gillitzer A, Meder K, Knorz A, Schrama D, Goebeler M, Schmidt M.   +8 more
europepmc   +1 more source

The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition. [PDF]

J Biol Chem
Nagasato-Ichikawa A, Murakami K, Aoki K, Okada M.   +3 more
europepmc   +1 more source

Protodioscin enhances Methotrexate-induced senescence and senolytic activity in HepG2 liver cancer spheroids by modulating cell cycle regulators and the TGF-β/p-Smad2-4 signaling pathway. [PDF]

Sci Rep
Jafaei Souq A, Ghanbari A, Tabandeh MR, Zamir Nasta T, Faramarzi A, Makalani F, Jalili C.   +6 more
europepmc   +1 more source

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. [PDF]

Front Oncol
Du S, Wang L, Chen C, Sun Y, Liu Q, Shi J, Zhang F, Wang K, Cui C.   +8 more
europepmc   +1 more source

Nobiletin mitigates benign prostatic hyperplasia by suppressing prostate cell proliferation through regulation of cell cycle progression, signaling pathways, transcription factor activity, and the androgen-signaling axis. [PDF]

Front Pharmacol
Song JH, Lee D, Hwang B, Hwang SK, Choo S, Jeong HJ, Kim H, Cha B, Yun SJ, Choi YH, Kim WJ, Moon SK.   +11 more
europepmc   +1 more source